C2N Diagnostics LLC - Product Pipeline Analysis, 2024 Update

Summary

C2N Diagnostics LLC (C2N Diagnostics) is a protein diagnostic and therapeutic discovery company that offers progressive neurodegeneration solutions. The company develops tools and assays for clinical drug development, preclinical drug discovery and early detection and assessment of neurodegenerative disorders. It offers products such as SILK-Ab and SISAQ-Ab assays. C2N Diagnostics' products are used for the measurement of kinetics, or in vivo metabolism, and absolute quantitation of brain derived proteins. The company also develops products used in the treatment of Huntington’s disease, Parkinson's disease, brain injury, amyotrophic lateral sclerosis and schizophrenia, among others. C2N Diagnostics is headquartered in St. Louis, Missouri, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company C2N Diagnostics LLC
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company


C2N Diagnostics LLC Company Overview
C2N Diagnostics LLC Company Snapshot
C2N Diagnostics LLC Pipeline Products and Ongoing Clinical Trials Overview
C2N Diagnostics LLC – Pipeline Analysis Overview
C2N Diagnostics LLC - Key Facts
C2N Diagnostics LLC - Major Products and Services
C2N Diagnostics LLC Pipeline Products by Development Stage
C2N Diagnostics LLC Ongoing Clinical Trials by Trial Status
C2N Diagnostics LLC Pipeline Products Overview
Diagnostic Test - Alzheimer's Disease
Diagnostic Test - Alzheimer's Disease Product Overview
Diagnostic Test - Brain Disease
Diagnostic Test - Brain Disease Product Overview
Diagnostic Test - Neurological Disease
Diagnostic Test - Neurological Disease Product Overview
Multi-Analyte Combination Assay
Multi-Analyte Combination Assay Product Overview
p-tau217 Blood Test
p-tau217 Blood Test Product Overview
p-tau217 Blood Test Clinical Trial
PrecivityAD2 Blood Test
PrecivityAD2 Blood Test Product Overview
PrecivityAD2 Blood Test Clinical Trial
C2N Diagnostics LLC - Key Competitors
C2N Diagnostics LLC - Key Employees
C2N Diagnostics LLC - Locations And Subsidiaries
Head Office
Recent Developments
C2N Diagnostics LLC, Recent Developments
Feb 24, 2025: C2N Diagnostics’ PrecivityAD2 Blood Test Receives MHRA Medical Device Certification in the United Kingdom
Jan 31, 2025: Study Highlights How C2N’s PrecivityAD2 Blood Biomarker Test Use Improves Clinical Decision-Making in the Evaluation for Alzheimer’s Disease
Jan 28, 2025: First Canadian Clinic To Offer c2n’s PRECIVITYAD2 Blood Test To Help Healthcare Providers Diagnose Alzheimer’s Disease, Joining Global Community in Embracing Breakthrough Technology
Jan 15, 2025: C2N Diagnostics Partners with The Michael J. Fox Foundation to Uncover New Links Between Parkinson’s Disease, Lewy Body Dementia and Alzheimer’s Disease
Nov 14, 2024: New Investment from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) Leads Efforts to Develop Standardization Materials for Leading Diagnostic Biomarker
Sep 30, 2024: C2N Diagnostics Receives $15 Million Program Related Investment from GHR Foundation to Develop Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease
Sep 25, 2024: Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (DxA) Invests More Than $7 Million in C2N Diagnostics' Blood Tests
Sep 25, 2024: C2N Receives Funding from Diagnostics Accelerator to Develop a Decentralized Clinical Mass Spectrometry Solution to Enable High-Performance Alzheimer’s Disease Testing Worldwide
Aug 23, 2024: Multiple Sclerosis Appears to Protect Against Alzheimer’s Disease
Aug 09, 2024: C2N signs deal with Unilabs to expand access for Alzheimer’s blood tests
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
C2N Diagnostics LLC Pipeline Products and Ongoing Clinical Trials Overview
C2N Diagnostics LLC Pipeline Products by Indication
C2N Diagnostics LLC Ongoing Clinical Trials by Trial Status
C2N Diagnostics LLC, Key Facts
C2N Diagnostics LLC, Major Products and Services
C2N Diagnostics LLC Number of Pipeline Products by Development Stage
C2N Diagnostics LLC Pipeline Products Summary by Development Stage
C2N Diagnostics LLC Ongoing Clinical Trials by Trial Status
C2N Diagnostics LLC Ongoing Clinical Trials Summary
Diagnostic Test - Alzheimer's Disease - Product Status
Diagnostic Test - Alzheimer's Disease - Product Description
Diagnostic Test - Brain Disease - Product Status
Diagnostic Test - Brain Disease - Product Description
Diagnostic Test - Neurological Disease - Product Status
Diagnostic Test - Neurological Disease - Product Description
Multi-Analyte Combination Assay - Product Status
Multi-Analyte Combination Assay - Product Description
p-tau217 Blood Test - Product Status
p-tau217 Blood Test - Product Description
p-tau217 Blood Test - The Swedish BioFINDER - Memory Clinic Study
p-tau217 Blood Test - The Swedish Biofinder 2 Study
PrecivityAD2 Blood Test - Product Status
PrecivityAD2 Blood Test - Product Description
PrecivityAD2 Blood Test - Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
PrecivityAD2 Blood Test - The Swedish BioFINDER Study: Early Diagnosis of Alzheimer's Disease - a Multidisciplinary Approach
C2N Diagnostics LLC, Key Employees
Glossary

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings